Fidelity Investments
CSTL icon

Fidelity Investments’s Castle Biosciences CSTL Stock Holding History

Fidelity Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Buy
55,871
+5,459
+11% +$122K ﹤0.01% 2897
2026
Q1 		$1.24M Buy
50,412
+8,126
+19% +$266K ﹤0.01% 2799
2025
Q4 		$1.64M Buy
42,286
+13,744
+48% +$443K ﹤0.01% 2678
2025
Q3 		$650K Buy
28,542
+4,542
+19% +$92.3K ﹤0.01% 2944
2025
Q2 		$490K Buy
24,000
+22,844
+1,976% +$423K ﹤0.01% 2965
2025
Q1 		$23.1K Buy
1,156
+75
+7% +$1.86K ﹤0.01% 4172
2024
Q4 		$28.8K Buy
1,081
+63
+6% +$1.92K ﹤0.01% 4078
2024
Q3 		$29K Sell
1,018
-202
-17% -$5.14K ﹤0.01% 4016
2024
Q2 		$26.6K Buy
1,220
+348
+40% +$7.75K ﹤0.01% 3939
2024
Q1 		$19.3K Sell
872
-73
-8% -$1.59K ﹤0.01% 4032
2023
Q4 		$20.4K Sell
945
-65
-6% -$1.14K ﹤0.01% 3938
2023
Q3 		$17.1K Buy
1,010
+349
+53% +$6.1K ﹤0.01% 3888
2023
Q2 		$9.07K Sell
661
-52
-7% -$1.05K ﹤0.01% 4179
2023
Q1 		$16.2K Sell
713
-61
-8% -$1.49K ﹤0.01% 3932
2022
Q4 		$18.2K Sell
774
-7
-0.9% -$162 ﹤0.01% 3811
2022
Q3 		$20K Buy
781
+224
+40% +$6.28K ﹤0.01% 3851
2022
Q2 		$12K Buy
557
+106
+24% +$2.46K ﹤0.01% 4049
2022
Q1 		$20K Buy
+451
New +$18.6K ﹤0.01% 4009
2021
Q4 		– Sell
-2
Closed – – 4411
2021
Q3 		$0 Sell
2
-2
-50% -$141 ﹤0.01% 4431
2021
Q2 		$0 Sell
4
-335,241
-100% -$22.1M ﹤0.01% 4329
2021
Q1 		$23M Sell
335,245
-247,706
-42% -$18.6M ﹤0.01% 1745
2020
Q4 		$39.1M Buy
582,951
+167,027
+40% +$9.05M ﹤0.01% 1421
2020
Q3 		$21.4M Buy
415,924
+112,456
+37% +$5M ﹤0.01% 1533
2020
Q2 		$11.4M Buy
+303,468
New +$10.4M ﹤0.01% 1767

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's CSTL Position: Q2 2026 in Review

Fidelity Investments increased its Castle Biosciences (CSTL) stake by 11% in Q2 2026, buying an estimated $122K and bringing the position to 55,871 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2897.

Fidelity Investments first reported a position in CSTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $39.1M in Q4 2020. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Fidelity Investments held 55,871 shares of Castle Biosciences worth $1.33M as of Q2 2026.
  • Fidelity Investments bought 5,459 Castle Biosciences shares in Q2 2026, an estimated $122K.
  • Castle Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2897 holding.
  • Fidelity Investments first reported a position in Castle Biosciences in Q2 2020 and has held it in 24 quarters since.
  • Fidelity Investments's Castle Biosciences position peaked at $39.1M in Q4 2020.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.